Kết quả điều trị bệnh Crohn ở trẻ em bằng liệu pháp sinh học tại Bệnh viện Nhi Trung ương

Abstract

Pediatric Crohn’s disease is increasing globally and poses significant therapeutic challenges. Biologic therapy, particularly anti-TNF-α agents, has demonstrated efficacy in managing the disease. Objective: To evaluate the treatment outcomes of Crohn’s disease in children using biologic therapy at the Vietnam National Children's Hospital. Materials and methods: We conducted a descriptive case series involving 38 pediatric patients diagnosed with Crohn’s disease and treated with Infliximab or Adalimumab between January 2016 and March 2025. Results: 60.5% of patients experienced disease onset after 6 years of age, with a male to female ratio of 1.1:1. The median time from diagnosis to initiation of biologic therapy was 4 months. By 3 months, 84.2% showed clinical response. The clinical remission rate improved from 56.8% at 6 months to 75.9% at 12 months. After 12 months, CRP, fecal calprotectin levels normalized in 57.9%, 51.7% of patients, respectively, while 31.1% achieved endoscopic remission. Dose intensification of anti-TNF-α therapy was required in 42.1% of cases. Conclusion: Biologic therapy is effective in achieving clinical response and remission, reducing inflammatory markers, and supporting mucosal healing in pediatric Crohn’s disease.